Teranode™ Software System Selected by National Institutes of Health’s Chemical Genomics Center
Teranode Corporation, the leading innovator of design automation software for the Life Sciences industry, today announced that the National Institutes of Health’s (NIH) Chemical Genomics Center (NCGC) will use the company’s award-winning technology, TERANODE Design Suite (TDS), to provide a platform for collaboration between the center and external organizations. TDS will be used to publish and exchange assay designs, screening protocols, and screening results. The goal of the collaboration is to accelerate the availability of chemical probes for research on biological pathways.
Established as part of the NIH Roadmap for Medical Research, NCGC is the first component of a nationwide network that will produce innovative chemical tools and libraries for use in biological research. As part of this effort, NCGC has chosen TDS as one component of a pilot installation for its informatics infrastructure. The TERANODE platform provides a standard collaboration infrastructure for working with outside organizations. While this project is in the early stages, the inclusion of TERANODE demonstrates its value and innovation in this emerging use of design tools.
“This is a pioneering initiative that, in time, may do for biological pathways what the Human Genome Project is doing for genetic knowledge. Swift, efficient collaboration among academic, non-profit, and commercial organizations will be crucial to its success,” said Dr. Christopher Austin, Director, NIH Chemical Genomics Center. “Our challenge is to convey large volumes of ever-changing protocol, experimental, and genomics information without having to lock ourselves and our collaborators into a fixed database system.”
Inclusion of TERANODE Design Suite will:
- support collaborative design for the diverse arrangement of high-throughput screening (HTS) protocols to be designed at NCGC;
- provide a flexible means for publishing and exchanging experimental data;
- provide collaborative authoring of biological pathways; and
- act as a model repository to be used by the broader research community to submit HTS requests.
“We’re honored to be working with such a prestigious organization as the NIH on a cutting-edge initiative to create new collaboration in the scientific community and accelerate the study of human diseases,” said Joseph Duncan, CEO for Teranode. “Our work with the NCGC demonstrates the value of design automation software to enable collaboration between scientists across organizational and physical boundaries to dramatically improve experimental productivity in each stage of R&D.”
About NIH Chemical Genomics Center (NCGC)
Using the Human Genome Project as a guiding example, the National Institutes of Health (NIH) Chemical Genomics Center is being created as part of the Molecular Libraries Screening Center Network initiative of the NIH Roadmap for Medical Research. The network’s mission is to apply the tools of small molecule screening and discovery to the development of chemical probe research tools, for use in the study of protein and cell functions, and biological processes relevant to physiology and disease.
For more information on the NIH Chemical Genomics Center project, please visit: http://www.genome.gov/NCGC .
About TERANODE Design Suite
Design automation software is purpose-built to close the informatics loop in R&D while leveraging the advances in laboratory automation and analytic tools. Closing the informatics loop in R&D requires: a holistic approach of model and data integration; a common repository that supports scientific collaboration, and cost-effective deployment to the individual user or enterprise process. TERANODE Design Suite provides the comprehensive set of capabilities that makes closed-loop informatics possible for Life Sciences R&D. TERANODE Design Suite can break the paradox of R&D productivity to deliver real leverage from advances in physical and process science.
About Teranode Corporation
Teranode Corporation, headquartered in Seattle, WA, is the leading innovator of design automation software to accelerate decision-making, collaboration, and compliance in the Life Sciences industry. The company, founded in 2002 to revolutionize the role that computing plays in Life Sciences, began with technologies invented by the founders at the University of Washington. TERANODE Design Suite is being used by leading pharmaceutical, biotechnology, research and academic organizations including Pfizer, AstraZeneca, St. Jude Children’s Research Hospital, and Fred Hutchinson Cancer Research Center.
For more information on Teranode please visit www.teranode.com
